Huahai Pharmaceutical Acquired 24.24% equity of Pu Lin Johnson

Huahai Pharmaceutical Co., Ltd. (Huahai Pharmaceutical) announced that the company intended to acquire the minority shareholder stake of 24.24% of Pu Lin Johnson Bio-Pharmaceutical Co., Ltd (Pu Lin Johnson). As of September 5, 2019, according to the share acquisition agreement, the transfer procedures of 88 million shares of the total share capital of Pu Lin Johnson have been completed.

Huahai Pharmaceutical now directly holds 24.24% shares of Pu Lin Johnson and 66.40% shares of the company through its wholly-owned subsidiary Huahai (USA) International Co., LTD. ( Huahai USA).

Founded in 1989, Huahai Pharmaceutical Co., Ltd. is headquartered in Zhejiang, China. Its business involves many sectors, such as chemical drugs, biological drugs, and trade.

Huahai Pharmaceutical Co., Ltd. is devoted to provide global patients with high-quality medical health products, and continuously improve product accessibility for people.

Pu Lin Johnson was founded by a wholly-owned subsidiary by Huahai USA in October 2009 in the Cayman Islands, with a registered capital of $50000. The company is mainly engaged in generic drug development, production, and sales business in US market research.